17159-84-1

Upstream product

• 67-56-1 methanol 
• 17159-83-0 4-<<(p-tolylsulfonyl)oxy>methyl>cyclohexanone 
• 104582-47-0 4-(methoxymethyl)cyclohexanone ethylene ketal 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 
• 26934-56-5 1,4-dioxaspiro[4.5]decan-8-ylmethyl 4-methylbenzenesulfonate 
• 1067233-36-6 1,1-bis(methyloxy)-4-[(methyloxy)methyl]cyclohexane 
• 96184-80-4 8-(methoxymethylene)-1,4-dioxaspiro<4.5>decane 
• 1232493-02-5 (4,4-diethoxycyclohexyl)methanol 
• 860469-35-8 ethyl 4,4-diethoxycyclohexane-1carboxylate 
• 934821-85-9 C₁₃H₂₄O₃ 
• 934821-87-1 methyl 4-(tetrahydro-2H-pyran-2-yloxy)cyclohexanecarboxylate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 

Downstream Products

• 934821-79-1 8-methoxymethyl-1,3-diaza-spiro[4.5]decane-2,4-dione 
• 31701-64-1 4-(methoxymethyl)cyclohex-2-enone 
• 1425971-64-7 1-{4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl}-4-(methoxymethyl)cyclohexanol 
• 1425971-65-8 1-{4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl}-4-(methoxymethyl)cyclohexanol 
• 1220389-67-2 3-(1-{4-[(methyloxy)methyl]cyclohexyl}-4-piperidinyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbonitrile 
• 1108720-81-5 (4-Methoxymethyl-cyclohexylidene)-acetic acid methyl ester 
• 919799-81-8 trans-4-methoxymethyl-cyclohexylamine hydrochloride 

Relevant academic research and scientific papers

Diastereoselective Intramolecular Hydride Transfer under Br?nsted Acid Catalysis

A diastereoselective hydride transfer process has been developed under Br?nsted acid-catalyzed reaction conditions using methyl ethers or acetals as hydride donors and tertiary alcohols or alkenes as precursors of carbocation. The method enables construction of complex molecules having multiple stereogenic centers from rather simple and readily available starting materials with predictable diastereoselective control.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: wherein R4, R6, R7, R8, Q, A, Y, n are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treat

Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids

The invention relates to novel alkoxyalkyl spirocyclic tetramic and tetronic acids of the formula (I), in which A, B, D, Q1, Q2, Q3, Q4, G, W, X, Y and Z are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or microbicides, and also to selective herbicidal compositions comprising, firstly, the alkoxyalkyl spirocyclic tetramic and tetronic acids and, secondly, at least one crop plant compatibility-improving compound.

BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS

The present invention relates to compounds of formula (I) wherein R1 and A are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS

The present invention relates to compounds of the formula (I) wherein R1, R2, X and n are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture,

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of Formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q and R1 are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating ps

UREA GLUCOKINASE ACTIVATORS

The invention provides a compound of general formula (I) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds

DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS

Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes. (I)